EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs

Panelists discuss how managing adverse events and selecting optimal treatment strategies remain key challenges in front-line EGFR-mutated, non–small cell lung cancer (mNSCLC) therapy, particularly when weighing the efficacy and toxicity profiles of available targeted therapies.

EP: 1.EGFR mNSCLC Front-Line: Treatment Options

EP: 2.EGFR mNSCLC: Challenges with Treatments in this Space

Now Viewing

EP: 3.EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs

EP: 4.PALOMA-3: Study Design and Baseline Characteristics

Recent Videos